Risk factors for the development of esophageal candidiasis among patients in community hospital

Sci Rep. 2021 Oct 19;11(1):20663. doi: 10.1038/s41598-021-00132-w.

Abstract

The aim of this study was to clarify risk factors for esophageal candidiasis (EC) in immunocompetent patients in a community hospital. 7736 patients who underwent esophagogastroduodenoscopy at our hospital from April 2012 to July 2018 were enrolled. The relationships between EC and the following factors: age, gender, body mass index, lifestyle, lifestyle-related diseases, medication, and endoscopic findings were analyzed. EC was observed in 184 of 7736 cases (2.4% morbidity rate). Multivariate analysis revealed that significant risk factors for the development of EC were: diabetes mellitus {odds ratio (OR): 1.52}, proton pump inhibitor (PPI) use (OR: 1.69), atrophic gastritis (AG) (OR: 1.60), advanced gastric cancer (OR: 4.66), and gastrectomy (OR: 2.32). When severe EC (Kodsi grade ≥ II) was compared to mild EC (grade I), the most significant risk factors were advanced gastric cancer (OR: 17.6) and gastrectomy (OR: 23.4). When considering the risk of AG and PPI use with EC development, the risk increased as follows: AG (OR: 1.59), PPI use (OR: 2.25), and both (OR: 3.13). PPI use, AG, advanced gastric cancer and post-gastrectomy are critical risk factors for the development of EC. We suggest close monitoring for EC development when PPIs are administered to patients with these factors.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Candidiasis / drug therapy
  • Candidiasis, Invasive / etiology*
  • Candidiasis, Invasive / microbiology
  • Diabetes Mellitus
  • Esophagitis
  • Esophagus / microbiology*
  • Esophagus / pathology
  • Esophagus / surgery
  • Female
  • Gastritis, Atrophic / complications*
  • Gastritis, Atrophic / microbiology
  • Hospitals, Community
  • Humans
  • Iatrogenic Disease / prevention & control
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Odds Ratio
  • Proton Pump Inhibitors / adverse effects
  • Risk Factors
  • Stomach Neoplasms / complications

Substances

  • Proton Pump Inhibitors